Harrow Inc (HROW)

$54.18 +0.19 (0.35%)
Market Cap 2.01B
Revenue (ttm) 199.61M
Net Income (ttm) -17.48M
EPS (ttm) N/A
PE Ratio 123.14
Forward PE 41.60
Profit Margin -8.76%
Debt to Equity Ratio 5.21
Volume 913,300
Avg Vol 547,640
Day's Range N/A - N/A
Shares Out 37.04M
Stochastic %K 96%
Beta 0.07
Analysts Strong Sell
Price Target $70.71

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
Jstr22
Jstr22 Feb. 28 at 7:26 PM
$HROW should settle back around $51 a week after earnings and then get to $70 by 27’
1 · Reply
Finnish_boy
Finnish_boy Feb. 28 at 2:10 PM
$HROW
1 · Reply
HROW200
HROW200 Feb. 27 at 9:02 PM
$HROW Large volume at closing! Someone is getting a little scared...
0 · Reply
HROW200
HROW200 Feb. 27 at 8:54 PM
$HROW This has been a very odd week for daily share price action. I think it bodes well that we finished strong each day.
1 · Reply
holdor910
holdor910 Feb. 27 at 4:08 PM
$HROW 9 new positions
1 · Reply
flash9875
flash9875 Feb. 27 at 2:45 PM
$HROW Friday morning strip tease…
0 · Reply
Finnish_boy
Finnish_boy Feb. 27 at 12:44 PM
$HROW HARROW $100 THIS YEAR. I have been unlucky in my investment career. I should have tons of more money atm. HARROW is easy money, not going to miss that. For example there is tungsten producer EQR Resourches $EQR.AX. I talked with many finns with that stock at 0.035 AUD. I tried to open new account but they wanted more info so i was tired to gather new info. The same with my IBKR account. Yes, those wasnt big problems. I was lazy. The stock is now 0.28 AUD. Stock is now up 700% and going likely much higher. It was totally no-brainer setup that nobody talked. At least i tried. I have identified amazing R/R setups, but my account tells different story. Have to keep going!!
2 · Reply
CFontina
CFontina Feb. 27 at 5:46 AM
$HROW fuck, Baum is rich now. I bet he's banging a lot of ho's these days.
0 · Reply
MrMoneyBags4
MrMoneyBags4 Feb. 26 at 10:01 PM
$HROW Whatever happens this ER- HROW is going to rocket by this summer IMO. Hoping I can use other investments to load up more but if it takes off before. Oh well.
0 · Reply
HROW200
HROW200 Feb. 26 at 6:09 PM
$HROW I was confused. Pass-through only deals with outpatient surgery. Harrow’s focus is now in office and will still be covered.
1 · Reply
Latest News on HROW
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Feb 18, 2026, 7:00 AM EST - 10 days ago

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Feb 17, 2026, 7:00 AM EST - 11 days ago

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Feb 2, 2026, 7:00 AM EST - 26 days ago

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update

Jan 22, 2026, 6:06 PM EST - 5 weeks ago

Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update

Harrow: Flirting With Missing 2025 Revised Guidance

Jan 12, 2026, 12:49 PM EST - 6 weeks ago

Harrow: Flirting With Missing 2025 Revised Guidance

Undercovered Dozen: USA Rare Earth, Santacruz Silver, Western Midstream, Visa And More

Dec 8, 2025, 11:31 AM EST - 2 months ago

Undercovered Dozen: USA Rare Earth, Santacruz Silver, Western Midstream, Visa And More

USAR V WES AGNC AGNCM AGNCN AGNCO

Harrow to Present at Two Investor Conferences in December

Nov 24, 2025, 7:00 AM EST - 3 months ago

Harrow to Present at Two Investor Conferences in December

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Nov 18, 2025, 7:00 AM EST - 3 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 2:11 PM EST - 3 months ago

Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript

Harrow Announces Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 3 months ago

Harrow Announces Third Quarter 2025 Financial Results

Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential

Nov 5, 2025, 12:31 PM EST - 4 months ago

Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Oct 27, 2025, 7:00 AM EDT - 4 months ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other

Oct 15, 2025, 9:03 PM EDT - 4 months ago

Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other

ImprimisRx Announces Leadership Changes

Oct 6, 2025, 7:00 AM EDT - 5 months ago

ImprimisRx Announces Leadership Changes

Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Sep 27, 2025, 12:27 AM EDT - 5 months ago

Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Harrow to Acquire Melt Pharmaceuticals

Sep 26, 2025, 7:00 AM EDT - 5 months ago

Harrow to Acquire Melt Pharmaceuticals

Harrow Launches Harrow Access for All (HAFA)

Sep 25, 2025, 4:05 PM EDT - 5 months ago

Harrow Launches Harrow Access for All (HAFA)

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 15, 2025, 7:00 AM EDT - 5 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Harrow: Buy A Blend Of Value And Growth

Sep 12, 2025, 10:57 AM EDT - 6 months ago

Harrow: Buy A Blend Of Value And Growth

Harrow: A Classical GARP Stock

Sep 9, 2025, 1:11 PM EDT - 6 months ago

Harrow: A Classical GARP Stock

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 5:57 PM EDT - 6 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 14, 2025, 11:09 PM EDT - 7 months ago

Harrow's Ambitious Guidance Puts It In The Proving Ground

Harrow: Exciting Times In Store

Aug 13, 2025, 5:39 PM EDT - 7 months ago

Harrow: Exciting Times In Store

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 2:47 PM EDT - 7 months ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 7 months ago

Harrow Announces Second-Quarter 2025 Financial Results

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 29, 2025, 7:00 AM EDT - 7 months ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 8 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 8 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 15, 2025, 10:38 AM EDT - 8 months ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 11, 2025, 5:47 PM EDT - 8 months ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Harrow: Immense Upside Potential

Jul 9, 2025, 2:52 PM EDT - 8 months ago

Harrow: Immense Upside Potential

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 18, 2025, 7:00 AM EDT - 9 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

I Am Swimming In Dividends With +7% Yields

Jun 13, 2025, 8:30 AM EDT - 9 months ago

I Am Swimming In Dividends With +7% Yields

UMH

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Jun 9, 2025, 7:00 AM EDT - 9 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow: Epic Growth & Operating Leverage On Full Display

May 28, 2025, 3:20 PM EDT - 9 months ago

Harrow: Epic Growth & Operating Leverage On Full Display

Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 10 months ago

Harrow to Present at Two Investor Conferences in May

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 10, 2025, 6:17 PM EDT - 10 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 10 months ago

Harrow Announces First-Quarter 2025 Financial Results

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

May 5, 2025, 7:00 AM EDT - 10 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 11 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Apr 10, 2025, 7:00 AM EDT - 11 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29, 2025, 4:30 PM EDT - 1 year ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 2:00 PM EDT - 1 year ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 28, 2025, 1:39 PM EDT - 1 year ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Jstr22
Jstr22 Feb. 28 at 7:26 PM
$HROW should settle back around $51 a week after earnings and then get to $70 by 27’
1 · Reply
Finnish_boy
Finnish_boy Feb. 28 at 2:10 PM
$HROW
1 · Reply
HROW200
HROW200 Feb. 27 at 9:02 PM
$HROW Large volume at closing! Someone is getting a little scared...
0 · Reply
HROW200
HROW200 Feb. 27 at 8:54 PM
$HROW This has been a very odd week for daily share price action. I think it bodes well that we finished strong each day.
1 · Reply
holdor910
holdor910 Feb. 27 at 4:08 PM
$HROW 9 new positions
1 · Reply
flash9875
flash9875 Feb. 27 at 2:45 PM
$HROW Friday morning strip tease…
0 · Reply
Finnish_boy
Finnish_boy Feb. 27 at 12:44 PM
$HROW HARROW $100 THIS YEAR. I have been unlucky in my investment career. I should have tons of more money atm. HARROW is easy money, not going to miss that. For example there is tungsten producer EQR Resourches $EQR.AX. I talked with many finns with that stock at 0.035 AUD. I tried to open new account but they wanted more info so i was tired to gather new info. The same with my IBKR account. Yes, those wasnt big problems. I was lazy. The stock is now 0.28 AUD. Stock is now up 700% and going likely much higher. It was totally no-brainer setup that nobody talked. At least i tried. I have identified amazing R/R setups, but my account tells different story. Have to keep going!!
2 · Reply
CFontina
CFontina Feb. 27 at 5:46 AM
$HROW fuck, Baum is rich now. I bet he's banging a lot of ho's these days.
0 · Reply
MrMoneyBags4
MrMoneyBags4 Feb. 26 at 10:01 PM
$HROW Whatever happens this ER- HROW is going to rocket by this summer IMO. Hoping I can use other investments to load up more but if it takes off before. Oh well.
0 · Reply
HROW200
HROW200 Feb. 26 at 6:09 PM
$HROW I was confused. Pass-through only deals with outpatient surgery. Harrow’s focus is now in office and will still be covered.
1 · Reply
flash9875
flash9875 Feb. 26 at 2:47 PM
$HROW who let the dogs out
0 · Reply
HROW200
HROW200 Feb. 26 at 12:28 AM
$HROW What do I want to learn next week from Mark? 1. How are January and February sales for Vevye, Iheezo, and Triesence? 2. When will BYQLOVI be available? 3. Is Harrow on schedule with all the planned new hires? 4. Where is Harrow at with Melt-300? Does Harrow have an accelerated timeline for it? Will Harrow market it for non-ophthalmology uses or license it? Where is Harrow at with licensing 300 and 210 with international partners? What am I missing?
5 · Reply
Finnish_boy
Finnish_boy Feb. 25 at 11:00 PM
$HROW Excited about earnings. I think mgt will comment about massive momentum going ahead. No idea about earnings reaction, SP is going higher in any case this year. I think markets are going much higher overall this year. NDVIA result was great. AI demand out of the roof. Some volatility is expected bc of geopolitical things. Twelve F-22 raptors headed into middle east from UK. But every dip is buying opportunity IMHO!
0 · Reply
Finnish_boy
Finnish_boy Feb. 25 at 9:02 PM
$HROW SP went from $40 to $47.. i think shorts try to sell this down after Q4 report.. if very strong, we can see bigger jump
0 · Reply
flash9875
flash9875 Feb. 25 at 6:07 PM
$HROW Dear Shorts: Please do not cover yet. Best to wait for this to climb to $65. Then you can cover and we can see the terror in your eyes. Also at that point, it will push the stock to $75 plus. thank you from all us longs.
0 · Reply
Finnish_boy
Finnish_boy Feb. 25 at 5:13 PM
$HROW
0 · Reply
Finnish_boy
Finnish_boy Feb. 25 at 5:06 PM
$HROW 10 P/S * >380M = ?
0 · Reply
Finnish_boy
Finnish_boy Feb. 25 at 5:05 PM
$HROW 7.5 P/S * 380M (next year rev) = 2850M / 37M shares = $77
1 · Reply
flash9875
flash9875 Feb. 25 at 2:53 PM
$HROW Where is that morning love…
0 · Reply
flash9875
flash9875 Feb. 25 at 2:42 PM
$HROW morning strip tease….
0 · Reply
Finnish_boy
Finnish_boy Feb. 24 at 11:33 PM
$HROW Great example how stupid markets reactions are: OCUL positive ph3 data that supports approval. Crashed and now back where it was. Yes i know the results were lower than expectations but stock should have been flat or little up vs crash. And if positive, then up like 50-100%. EYPT has ph3 data readout in summer. But yea, there is need for Opuviz anyways. EYLEA biosimilars will remain affordable option. I will never play again bios (pre readout), never. I have no edge.
2 · Reply
Mega_Moons
Mega_Moons Feb. 24 at 5:21 PM
Caught a few of @TheMorningStew alerts over the last few weeks that went crazy! Give him a follow 🔥 $TOMZ $CHYM $ATOM.X $HROW
0 · Reply